All In Biotech

BLA 761063 · Eli Lilly and CO

Emgality

Galcanezumab-Gnlm · Injection

NovelBreakthrough therapy

Last checked: Nov 20, 2026Latest source record: Jun 5, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Sep 27, 2018

Approved uses

2

Original approval plus efficacy supplements

Registered trials

32

12 Phase 3, 5 recruiting

FAERS reports

32,317

4,007 serious, 89 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 5, 2026.

EMGALITY ® is a calcitonin-gene related peptide antagonist indicated in adults for the: preventive treatment of migraine. ( 1.1 ) treatment of episodic cluster headache. ( 1.2 ) 1.1 Migraine EMGALITY is indicated for the preventive treatment of migraine in adults. 1.2 Episodic Cluster Headache EMGALITY is indicated for the treatment of episodic cluster headache in adults.

Mechanism: Galcanezumab-gnlm is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 4, 2019 Supplement 3 · Efficacy · priority review Breakthrough therapyLabelLetter
  • Sep 27, 2018 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
1 products under this application
  • EMGALITY · GALCANEZUMAB-GNLM 120MG/ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Galcanezumab" as an intervention, any sponsor and status, largest first.

All 32 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • injection site pain7,789
  • migraine3,158
  • underdose2,919
  • headache2,509
  • drug ineffective1,980
  • product dose omission issue1,766
  • injection site haemorrhage1,666
  • incorrect dose administered1,197
  • injection site erythema1,145
  • accidental underdose1,068
  • nausea852
  • injection site swelling827

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20154
20164
20176
2018140
20194,657
20206,640
20214,645
20223,737
20232,977
20243,150
20253,672
20262,685

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 130 on PubMed

Sponsor: Eli Lilly

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.